Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-23Clinical Trial Update: AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer [Phase 1, Phase 2]
A clinical trial evaluating the combination of bevacizumab and bemarituzumab for gynecologic cancers (endometrial, ovarian, and cervical) ha…
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer [Phase 1, Phase 2]
A master protocol Phase 1/2 trial sponsored by AstraZeneca evaluating biomarker-guided anticancer agents for advanced/recurrent ovarian canc…
-
CLINICAL_TRIALS withdrawal · 2026-02-11Clinical Trial Update: Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs [NA]
A clinical trial evaluating an individual decision aid for colorectal, breast, and ovarian cancer screening in Sweden has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer [NA]
Withdrawn clinical trial evaluating a virtual mental health intervention for fear of progression in women with high-risk or stage III-IV gyn…
-
CLINICAL_TRIALS withdrawal · 2025-11-28Clinical Trial Update: (VELA) Study of BLU-222 in Advanced Solid Tumors [Phase 1]
A Phase 1 study of BLU-222 in advanced solid tumors has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-11-27EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, o…
-
CLINICAL_TRIALS withdrawal · 2025-09-23Clinical Trial Update: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 [Phase 2, Phase 3]
The REFRaME-O1 trial evaluating Luveltamab Tazevibulin versus investigator's choice chemotherapy for FOLR1-expressing ovarian cancer and rel…
-
CLINICAL_TRIALS withdrawal · 2025-08-29Clinical Trial Update: MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii
A clinical trial investigating molecular characterization and treatment of thyroid carcinoma arising in struma ovarii (ovarian cancer) was w…
-
CLINICAL_TRIALS withdrawal · 2025-07-30Clinical Trial Update: HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Alaunos Therapeutics reports termination of a Phase I/II autologous TCR-T cell trial across several solid tumors. The study focused on HLA t…
-
CLINICAL_TRIALS withdrawal · 2025-07-01Clinical Trial Update: A Study to Investigate LYL797 in Adults With Solid Tumors [Phase 1]
Lyell Immunopharma's Phase 1 study of LYL797 in adults with solid tumors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-06-03Clinical Trial Update: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]
Withdrawal of a Phase 1/2 trial evaluating adding ASTX660 (tolinapant) to paclitaxel with or without bevacizumab in patients with recurrent …
-
CLINICAL_TRIALS withdrawal · 2025-05-23Clinical Trial Update: Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer [Phase 1, Phase 2]
Withdrawal notice for a Phase 1/Phase 2 trial of Niraparib with selenium in BRCA-negative, platinum-resistant fallopian tube, ovarian, and p…
-
CLINICAL_TRIALS withdrawal · 2025-04-06Clinical Trial Update: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi [Phase 2]
A Phase 2 trial evaluating dostarlimab plus niraparib for relapsed ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn.…
-
CLINICAL_TRIALS withdrawal · 2025-03-05Clinical Trial Update: PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial of PEP-DC and OC-DC vaccines for ovarian cancer has been withdrawn. The trial was listed as Withdrawn in Clinical…
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy [Phase 1, Phase 2]
The QUILT-3.051 trial evaluating the NANT Ovarian Cancer Vaccine in epithelial ovarian cancer has been withdrawn in subjects who progressed …
-
CLINICAL_TRIALS withdrawal · 2025-02-12Clinical Trial Update: Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency [Phase 2]
Phase 2 trial of upfront maintenance olaparib in advanced BRCA wild-type ovarian cancer with homologous recombination deficiency has been wi…
-
CLINICAL_TRIALS withdrawal · 2025-02-12Clinical Trial Update: Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer [Phase 3]
A Phase 3 trial comparing Avastin plus chemotherapy with a cancer stem cell test–guided approach in recurrent ovarian cancer has been withdr…
-
CLINICAL_TRIALS withdrawal · 2025-01-15Clinical Trial Update: A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors [Phase 1]
A Phase 1 trial evaluating ASP1893 in adults with CLDN6-positive solid tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-01Clinical Trial Update: Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating neoadjuvant chemotherapy with or without HCW9218 for metastatic advanced ovarian cancer has been withdrawn.
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors [Phase 1]
A Phase 1 trial evaluating ZEN003694 in combination with niraparib for metastatic or recurrent solid tumors, including ovarian cancer, has b…
-
CLINICAL_TRIALS withdrawal · 2024-08-20Clinical Trial Update: Intraperitoneal LSTA1 in CRS-HIPEC [Phase 1]
The document reports the withdrawal of a Phase 1 trial of intraperitoneal LSTA1 for peritoneal cancers. The conditions include colorectal ca…
-
CLINICAL_TRIALS withdrawal · 2024-08-13Clinical Trial Update: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors [Phase 1, Phase 2]
A phase 1/2 trial evaluating TNG348 alone and in combination with a PARP inhibitor for BRCA1/2-mutant or HRD-positive solid tumors has been …
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer [Phase 1]
Phase 1 clinical trial investigating neuroinflammation and age-related brain pathology as potential mechanisms of cognitive impairment in ov…
-
CLINICAL_TRIALS withdrawal · 2022-04-15Clinical Trial Update: Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers [Phase 2, Phase 3]
Clinical trial evaluating secondary cytoreductive surgery in platinum-resistant recurrent ovarian cancer has been withdrawn.